Mallinckrodt

Mallinckrodt. Mallinckrodt is a global specialty pharmaceutical company with a complex history dating back to the 19th century. It develops, manufactures, and markets a portfolio of branded and generic pharmaceuticals, as well as imaging agents and contrast media. The company has been a significant but controversial player in the opioid epidemic in the United States and has faced extensive legal and financial challenges related to its business practices.

History

The company was founded in 1867 in St. Louis, Missouri by brothers Edward Mallinckrodt, Otto Mallinckrodt, and Gustav Mallinckrodt, initially focusing on the manufacture of fine chemicals and pharmaceutical ingredients. It grew through the 20th century, becoming a major supplier of radioactive isotopes for medical and research purposes following collaborations with institutions like the United States Atomic Energy Commission. In 2000, the company was acquired by Tyco International, which later spun off its healthcare businesses into Covidien in 2007. The pharmaceutical division of Covidien was subsequently spun off as an independent, publicly traded company again in 2013, resuming the Mallinckrodt name and trading on the New York Stock Exchange. Key leadership during its modern era included former CEO Mark C. Trudeau.

Products and operations

Mallinckrodt's portfolio is centered on specialty branded pharmaceuticals, hospital products, and generics. Its most notable and controversial product is Acthar Gel, a corticotropin-based therapy for conditions including infantile spasms and multiple sclerosis relapses, which became a major revenue driver. Other significant branded products include the injectable analgesic Ofirmev and INOMAX, an inhaled nitric oxide gas used for respiratory conditions in neonates. The company also manufactures a range of generic opioid medications, such as oxycodone and hydrocodone, and operates a substantial active pharmaceutical ingredient business. Its operations span manufacturing and research facilities across North America, Europe, and Asia.

Legal and regulatory issues

The company has been embroiled in numerous high-profile legal and regulatory controversies, primarily related to its marketing of opioid medications and the pricing of Acthar Gel. It faced investigations by the United States Department of Justice, the Drug Enforcement Administration, and multiple State Attorneys General concerning its role in the opioid crisis. In 2020, Mallinckrodt reached a $1.6 billion global settlement to resolve thousands of lawsuits alleging it fueled the opioid epidemic through deceptive marketing practices. Separately, it faced scrutiny from the U.S. Securities and Exchange Commission and congressional committees over massive price increases for Acthar Gel. These issues culminated in the company filing for Chapter 11 bankruptcy protection in 2020 to manage its overwhelming liabilities.

Financial performance

Mallinckrodt's financial trajectory has been volatile, heavily influenced by its reliance on Acthar Gel and the costs associated with litigation. Following its 2013 spin-off, the company reported substantial revenue, with Acthar Gel alone generating over $1 billion annually at its peak. However, earnings were severely impacted by legal settlements, restructuring charges, and generic competition. The 2020 bankruptcy filing led to a significant debt restructuring and the establishment of a national opioid settlement trust. Its stock, once a component of the S&P 500, was delisted from the New York Stock Exchange and experienced extreme volatility, rendering shareholder equity nearly worthless as the company reorganized under bankruptcy court supervision.

Corporate structure

Following its bankruptcy reorganization, which was confirmed in 2023, Mallinckrodt emerged as a privately held company owned largely by its former creditors. Its corporate structure was streamlined, with significant assets, including the INOMAX business, sold to other entities like Linde plc to fund settlements. The restructured entity focuses on a reduced portfolio of specialty brands and generics. Governance shifted from a publicly traded board to one controlled by representatives of major financial stakeholders, including debtor-in-possession lenders and the opioid settlement trust established as part of its bankruptcy plan.

Category:Pharmaceutical companies of the United States Category:Companies based in St. Louis Category:Companies that filed for Chapter 11 bankruptcy in 2020